Implications of all the available evidence
INFLUENZA
Our results demonstrate a potentially better approach for boosting than is currently pursued with whole Spike vaccines targeting progressive generations of omicron variants. These vaccines focus the immune response to the RBD, the primary target for neutralising antibodies, while simultaneously avoiding imprinted responses against non-RBD Spike epitopes. As they appear to be capable of augmenting immune responses against a wide range of variants, there is a strong case to proceed to a Phase 2 study for both candidates. There is definite potential for both protein and mRNA combination vaccines (e.g. COVID with influenza, RSV, etc), because of the reduced ‘payload’ required for the COVID component (compared to whole Spike).